Immunotech Laboratories

Immunotech Laboratories is a small U.S.-listed biotechnology company focused on immune-modulating therapeutics derived from its Inactivated Pepsin Fraction platform. The company has historically centered its pipeline on ITV-1, also referred to in some materials as ImmunH, for HIV/AIDS and related infectious-disease applications, with development activity conducted in part through its Bulgarian affiliate. Public materials describe additional exploratory programs in hepatitis, prenatal and pediatric HIV/AIDS, a preventive HIV vaccine concept, and stem-cell media research, but the company appears to have limited current public disclosure and a sparse institutional operating footprint. IMMB remains quoted on the OTC market and is still an active corporate entity, but available evidence suggests it is a very small, thinly traded development-stage company rather than a commercial-stage biotechnology business. A biotech analyst should view its historical claims and pipeline breadth cautiously because much of the detailed program information comes from older company materials and affiliated websites rather than robust recent regulatory or peer-reviewed disclosures.